ADMET

ADME Strategy and Challenges for Bifunctional Degradation Activating Compounds (BiDAC degraders)

Targeted Protein Degradation has the potential to transform treatment of disease. C4T’s TORPEDO platform enables the design of potent, selective and orally available targeted protein degraders including monofunctional or MonoDAC degraders and heterobifunctional or BiDAC degraders and has delivered a robust pipeline of preclinical candidates. The presentation will discuss in-vitro and in-vivo strategies and challenges in the context of BiDAC degrader drug discovery. As a case study, preclinical ADME properties of CFT8634, a potent, selective and orally available BiDAC degrader of BRD9 for the treatment of SMARCB1-perburbed cancers will be discussed.